iCAN aims to improve outcomes and quality of life of cancer patients.
We do this through cutting-edge research focused on improving understanding in immuno-oncology, tumor microenvironment and development of disease resistance.
Our research projects leverage the iCAN discovery platform to identify new targets and solutions for diagnosing and treating cancer.
The iCAN discovery platform links molecular profiling of tumors with broader health data of cancer patients, acting as a catalyst for breakthrough research and technologies.
The scale of data – 15,000 samples across different cancer types will be profiled by 2026 – enables real impact and broad studies across different cancer types.
The platform will enable an improved understanding of the complex interplay between cancer cells and the host.
Our approach is to keep the patient in the focus in all activities in developing a research and innovation hub in digital precision cancer medicine.
At the center of the ecosystem is the iCAN discovery platform leveraged in collaborative partnerships among researchers and the life science industry.
Digitaalisen yksilöllisen syöpälääketieteen lippulaiva iCAN ja Suomen Syöpäinstituutin säätiö järjestävät 22.-23.9.2022 symposiumin Mission: Possible – Read More »
iCAN Steering Board supported today the nomination of Satu Mustjoki as iCAN’s new Scientific Director. Read More »
The webinar held on May 11, 2022 focused on how to implement high-quality, harmonized RWD/RWE Read More »
The iCAN-FCAI workshop will bring together top researchers from both flagships, with the goal to Read More »
Indeed! And more to come later today!
Nelli Sjöblom Dept Pathology @HelsinkiUniMed : NGS screening may improve detection of biliary neoplasia in PSC patients
Don’t miss the feedback session to 2023-26 proposals by the Scientific and Impact Advisory Board today 18:05-18:30 after last session at the symposium https://ican.fi/symposium2022/
